Shilpa Medicare Receives SEC Approval for OERIS Extended-Release Injection
NiveshIQ
NSE: SHILPAMED · Healthcare
Shilpa Medicare Ltd.
₹961.15▲ ₹21.25 (+2.26%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on SHILPAMED. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Shilpa Medicare Ltd.
Shilpa Medicare Limited is a leading manufacturer and seller of active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation with a global presence. The company's core business is driven by its diverse portfolio of oncology and non-oncology APIs, including anastrozole, axitinib, and erlotinib HCL, among others. Recently, Shilpa Medicare reported a strong Q1 FY27 performance, with revenue growing 43% year-over-year to ₹469 crore and profit increasing by 115%. The company's consolidated net sales for the quarter ended June 2026 stood at ₹465.78 crore, representing a 44.9% year-over-year growth. Shilpa Medicare's competitive position is supported by its robust product pipeline, strategic partnerships, and expandin
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹1,152 Cr +10.10% | ₹1,287 Cr +11.70% | ₹1,539 Cr +19.60% |
| EBITDA Margin | 20.75% | 24.40% | 28.89% |
| Net Profit | ₹32.00 Cr -203.20% | ₹79.00 Cr +146.90% | ₹214.05 Cr +170.90% |
| EPS | ₹1.83 | ₹4.00 | ₹12.44 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Shilpa Medicare Limited Declares Final Dividend for the Financial Year Ended March 31, 2026
Shilpa Medicare Limited Declares Final Dividend for the Financial Year Ended March 31, 2026
🔒
+ 3 more stories about Shilpa Medicare Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹466 Cr, PAT ₹101 Cr, EPS ₹5.16, EBITDA margin 29.9%. Growth context: revenue QoQ +6.6%, PAT QoQ +56.5%. Street verdict: strong beat, revenue surprise +1.3%, PAT surprise +29.0%.
Near-term growth is likely to be driven by product launches, approvals, and therapy-mix improvement, with successful exe...
In FY26, the Company reported revenue of ₹1, 539 Cr, PAT of ₹214 Cr, an EBITDA margin of 28.9%, and EPS of ₹12.44, repre...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for SHILPAMED
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track SHILPAMED alongside your other holdings
Unlock full SHILPAMED research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Shilpa Medicare Ltd.?
NiveshIQ detects active intelligence signals for Shilpa Medicare Ltd. (SHILPAMED) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Shilpa Medicare Ltd.?
Shilpa Medicare Ltd. operates in the Healthcare sector with a market capitalisation of ₹848,825.1L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.